LDS/Medical Tests/Coagulation Factor XI Inhibitor Screen, Plasma

Coagulation Factor XI Inhibitor Screen, Plasma

Factor XI (FXI) deficiency, historically referred to as hemophilia C, is an autosomal inherited bleeding disorder characterized by variable bleeding risk, most commonly following trauma or surgical procedures rather than spontaneous hemorrhage. Bleeding severity correlates poorly with FXI activity level and is strongly influenced by the site of injury, with tissues that have high fibrinolytic activity, such as the oral cavity, genitourinary tract, and tonsils, being particularly susceptible. Menorrhagia may occur in affected women, often influenced by additional hemostatic factors.

In rare cases, patients with congenital FXI deficiency may develop acquired inhibitors to factor XI. These neutralizing antibodies typically arise after exposure to plasma products or FXI concentrates and have also been reported following exposure to Rh immunoglobulin. Acquired FXI inhibitors may also occur in patients without known congenital deficiency, particularly in association with autoimmune disease, malignancy, gastrointestinal disease, or advanced age. Unlike classic acquired hemophilia A, spontaneous bleeding is uncommon; however, affected patients are at high risk for prolonged or excessive bleeding during surgery or trauma.

Clinically, the presence of a factor XI inhibitor should be suspected when the activated partial thromboplastin time (aPTT) remains prolonged despite appropriate replacement therapy or fails to correct on mixing studies. Because acquired FXI inhibitors are extremely rare, laboratory confirmation using an inhibitor screen and quantification is essential to guide diagnosis and management. Identification of an inhibitor has important therapeutic implications, including avoidance of FXI concentrates, use of bypassing agents or antifibrinolytics, and consideration of immunosuppressive therapy in select cases.

  • Detection of acquired inhibitors to factor XI in patients with unexplained bleeding or poor response to replacement therapy
  • Evaluation of persistent aPTT prolongation that does not correct on mixing studies
  • Guidance for perioperative and transfusion management in patients with suspected or confirmed factor XI inhibitors Monitoring patients at risk of inhibitor development following plasma exposure or factor XI replacement
Normal individuals do not have detectable factor XI inhibitors. Detection of an inhibitor indicates the presence of neutralizing antibodies to FXI and should be quantified and reported in Bethesda units (or equivalent). Results must be interpreted in conjunction with FXI activity levels, mixing study results, and the patient’s clinical presentation.
Factor XI Activity Assay Reference Range
Adults 55-150%
Neonates > or = 10%

 

Factor XI Inhibitor Screen Result / Reference
Screen Result Negative
General factor Bethesda units < or = 0.5 Bethesda units
Factor XI inhibitor (Bethesda titer) assay; aPTT-based test system.

Platelet-poor plasma on 3.2% sodium citrate (Light-blue top) vial, 1 mL minimum.

Patient must not be receiving warfarin or heparin therapy. 

Stability

  • Ambient: 4 hrs.
  • Refrigerated: unfavorable
  • Frozen: 2 weeks
PTT, aPTT, platelet count, PT, CBC, vWF, comprehensive metabolic panel, fibrinogen, factor IX gene mutation analysis, liver function panel, platelet function analysis.
3 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login